BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/21/2024 7:03:24 AM | Browse: 169 | Download: 812
 |
Received |
|
2024-06-18 19:02 |
|
Peer-Review Started |
|
2024-06-18 19:02 |
|
First Decision by Editorial Office Director |
|
2024-08-15 20:54 |
|
Return for Revision |
|
2024-08-15 20:54 |
|
Revised |
|
2024-08-28 17:43 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-09-19 02:45 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-19 13:03 |
|
Articles in Press |
|
2024-09-19 13:03 |
|
Edit the Manuscript by Language Editor |
|
2024-09-23 05:07 |
|
Typeset the Manuscript |
|
2024-09-27 02:04 |
|
Publish the Manuscript Online |
|
2024-10-21 07:03 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wei-Hua Cao, Ya-Qin Zhang, Xin-Xin Li, Zi-Yu Zhang and Ming-Hui Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The National Key Research and Development Program |
2022YFC2603500 and 2022YFC2603505 |
| Beijing Municipal Health Commission High-Level Public Health Technical Personnel Construction Project |
Discipline leader-03-26 |
| The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority |
XXZ0302 |
| The Capital Health Research and Development of Special Public Health Project |
2022-1-2172 |
| Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support |
XMLX 202127 |
|
| Corresponding Author |
Ming-Hui Li, MD, PhD, Chief Doctor, Professor, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wuhm2000@sina.com |
| Key Words |
Hepatitis B virus; Hepatocellular carcinoma; Immune checkpoint inhibitors; Peginterferon alpha; Systematic treatment |
| Core Tip |
Hepatitis B virus (HBV) infection interacts with tumor microenvironment (TME) through a highly complex and intertwined signaling pathway, which results in a special TME in hepatocellular carcinoma (HCC). Due to changes in the TME, tumor cells can evade immune surveillance by inhibiting tumor-specific T cell function through CTLA-4 and programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1). Interferon, as an immune factor with rich biological activity, can improve the TME of HBV-HCC through various pathways. Currently, the systematic treatment of HCC has gradually come out of the dilemma. In addition to the continuous emergence of new multi-target anti-vascular tyrosine kinase inhibitor drugs, immune checkpoint inhibitors have opened up a new situation for the systematic treatment of HCC, and the disease characteristics of patients included in global clinical studies are different from those of Chinese patients. Therefore, whether a group of HCC patients with HBV background and poor prognosis in China can also benefit from immunotherapy is a widely concerned issue. |
| Publish Date |
2024-10-21 07:03 |
| Citation |
Cao WH, Zhang YQ, Li XX, Zhang ZY, Li MH. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. World J Hepatol 2024; 16(10): 1158-1168 |
| URL |
https://www.wjgnet.com/1948-5182/full/v16/i10/1158.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v16.i10.1158 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
